NeuroVive resolves on a Rights issue of MSEK 123.8 for continued drug development, and new publication date of the 2018 Year End Report
Lund, Sweden, 10 December 2018 - NeuroVive Pharmaceutical AB (publ) (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces that the Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or "the Company") on 10 December 2018 resolved, subject to approval by the Extraordinary General Meeting, to issue shares with preferential rights to existing shareholders ("Rights issue") to enable continued drug development in its broad project portfolio. Upon full subscription to the Rights issue, the Company will receive approximately MSEK 123.8 before issuance costs. The Board of Directors of